<![CDATA[The Long Game]]>The Long Game is a podcast that demystifies the science shaping our lives, and explores how great ideas built in Scotland become real-world medicines, devices, and companies at the cutting edge of life sciences.

]]>https://playthelonggame.ukRiverside.fm (https://riverside.com)Mon, 02 Nov 2026 19:44:05 GMTMon, 30 Mar 2026 19:50:31 GMT60Sandy & Ross<p>The Long Game is a podcast that demystifies the science shaping our lives, and explores how great ideas built in Scotland become real-world medicines, devices, and companies at the cutting edge of life sciences.</p>episodicSandy & Rosssandyweir0@gmail.comno<![CDATA[The New Body Economy Part 7: Peptides- Why Is Everyone Suddenly Taking Them?]]>In this episode, Sandy and Ross delve into the world of peptides, discussing their uses, risks, and the burgeoning market surrounding them. They explore specific peptides like BPC 157 and Melanotan, highlighting the lack of regulation and scientific backing for many products available online. The conversation delves into the complexities of peptide medicines, their market dynamics, regulatory challenges, and the future of peptide research. It also touches on personal anecdotes and the importance of evidence in the context of wellness optimization.

Key Takeaways

  • Peptides are gaining popularity
  • Regulation and safety are concerns Peptide medicines require rigorous testing
  • Consumer demand drives peptide market
]]>5a8ebedc-2798-4e5e-895f-ee5ea7bc3b73Mon, 26 Oct 2026 20:19:03 GMT<p>In this episode, Sandy and Ross delve into the world of peptides, discussing their uses, risks, and the burgeoning market surrounding them. They explore specific peptides like BPC 157 and Melanotan, highlighting the lack of regulation and scientific backing for many products available online. The conversation delves into the complexities of peptide medicines, their market dynamics, regulatory challenges, and the future of peptide research. It also touches on personal anecdotes and the importance of evidence in the context of wellness optimization.</p><p>Key Takeaways</p><ul><li>Peptides are gaining popularity</li><li>Regulation and safety are concerns Peptide medicines require rigorous testing</li><li>Consumer demand drives peptide market</li></ul>no00:57:48130The New Body Economy Part 7: Peptides- Why Is Everyone Suddenly Taking Them?full<![CDATA[The New Body Economy Part 6: Silicon Valley Comes for the NHS]]>The NHS has some of the most valuable health data in the world and that makes it both a goldmine and a battleground.

In the latest episode of The Long Game, Sandy Weir and Ross Cagan pull apart the promise, the politics, and the very real risks of letting Silicon Valley companies help run the systems behind your care. They start with the Royal Free and DeepMind case, where 1.6 million patient records were shared without patients being individually asked for consent, then move to the bigger question now facing the NHS: what happens when companies like Palantir sit at the centre of the data infrastructure that powers care, research, and AI?

You'll discover why NHS data is so attractive to technology companies, what “data processor” vs “data controller” actually means in practice, and why trust can collapse even when the legal basis looks sound.

Sandy and Ross break down the hidden danger of vendor lock-in, the importance of interoperability and exit planning, and why standardised platforms may matter as much as the software itself.

We also get into the upside that keeps this conversation from becoming anti-tech. Ambient AI is already cutting documentation time dramatically, some pilots are reportedly slashing admin workloads by 80%, and linked data can improve diagnosis, scheduling, discharge, and research at scale. But those gains only matter if the public can see what they are getting back. The episode also revisits care.data, the NHS rollout that spent over a million pounds mailing leaflets to 22 million households only to collapse under public backlash, and the WannaCry attack, which showed how fragile healthcare infrastructure becomes when systems are outdated and security is weak.

The message is clear; in health data, trust is infrastructure. Essential listening if you care about AI in healthcare, public data, NHS reform, or the future of who gets to profit from the information we all help create.

The final question is the one that matters most, what should the public get back when its data creates private value?

]]>41f93482-2ce6-478b-8554-27ae40afd804Thu, 15 Oct 2026 11:00:27 GMT<p>The NHS has some of the most valuable health data in the world and that makes it both a goldmine and a battleground.</p><p>In the latest episode of The Long Game, Sandy Weir and Ross Cagan pull apart the promise, the politics, and the very real risks of letting Silicon Valley companies help run the systems behind your care. They start with the Royal Free and DeepMind case, where 1.6 million patient records were shared without patients being individually asked for consent, then move to the bigger question now facing the NHS: what happens when companies like Palantir sit at the centre of the data infrastructure that powers care, research, and AI?</p><p>You'll discover why NHS data is so attractive to technology companies, what “data processor” vs “data controller” actually means in practice, and why trust can collapse even when the legal basis looks sound.</p><p>Sandy and Ross break down the hidden danger of vendor lock-in, the importance of interoperability and exit planning, and why standardised platforms may matter as much as the software itself.</p><p>We also get into the upside that keeps this conversation from becoming anti-tech. Ambient AI is already cutting documentation time dramatically, some pilots are reportedly slashing admin workloads by 80%, and linked data can improve diagnosis, scheduling, discharge, and research at scale. But those gains only matter if the public can see what they are getting back. The episode also revisits care.data, the NHS rollout that spent over a million pounds mailing leaflets to 22 million households only to collapse under public backlash, and the WannaCry attack, which showed how fragile healthcare infrastructure becomes when systems are outdated and security is weak.</p><p>The message is clear; in health data, trust is infrastructure. Essential listening if you care about AI in healthcare, public data, NHS reform, or the future of who gets to profit from the information we all help create.</p><p>The final question is the one that matters most, what should the public get back when its data creates private value?</p>no00:40:03129The New Body Economy Part 6: Silicon Valley Comes for the NHSfull<![CDATA[The New Body Economy Part 5: The Newborn Genome]]>The future of newborn screening sounds simple until you ask the hard question: should every baby have their whole genome sequenced at birth?

Sandy Weir and Ross Cagan unpack the promise, the technology, and the uncomfortable trade-offs behind one of the biggest shifts in modern healthcare. With the NHS Generation Study already sequencing newborns across England, this episode explores how ultra-fast genome reading could catch rare, treatable diseases before symptoms appear, potentially sparing families years of uncertainty, misdiagnosis, and delayed care. But as Sandy and Ross make clear, reading DNA is only the beginning.

They break down:

  • why whole genome sequencing could transform rare disease diagnosis
  • what the Generation Study is actually screening for, including 223 rare conditions across more than 500 genes
  • why variants of unknown significance can create anxiety instead of answers
  • how penetrance, adult-onset risk, and future autonomy complicate consent
  • why storing a baby's genome raises questions about access, reanalysis, and lifetime data control

Ross also explains why the real bottleneck is not sequencing speed, but interpretation, counselling, follow-up, and the full care pathway that turns data into something useful.

Sandy pushes on the fairness question too: if genomic foresight becomes a public good, who gets access, who pays, and what happens if it becomes another divide between wealthy families and everyone else?

If you care about genetics, public health, medical ethics, or the future of personalised medicine, this conversation is essential listening. It is a sharp, accessible look at how close we are to sequencing every baby, and why the real debate is not whether we can do it, but whether we should.

]]>https://www.playthelonggame.uk/84fa285e-6312-4c31-8a58-145d7ea80709Thu, 08 Oct 2026 20:31:37 GMT<p>The future of newborn screening sounds simple until you ask the hard question: should every baby have their whole genome sequenced at birth?</p><p>Sandy Weir and Ross Cagan unpack the promise, the technology, and the uncomfortable trade-offs behind one of the biggest shifts in modern healthcare. With the NHS Generation Study already sequencing newborns across England, this episode explores how ultra-fast genome reading could catch rare, treatable diseases before symptoms appear, potentially sparing families years of uncertainty, misdiagnosis, and delayed care. But as Sandy and Ross make clear, reading DNA is only the beginning.</p><p>They break down:</p><ul><li>why whole genome sequencing could transform rare disease diagnosis</li><li>what the Generation Study is actually screening for, including 223 rare conditions across more than 500 genes</li><li>why variants of unknown significance can create anxiety instead of answers</li><li>how penetrance, adult-onset risk, and future autonomy complicate consent</li><li>why storing a baby's genome raises questions about access, reanalysis, and lifetime data control</li></ul><p>Ross also explains why the real bottleneck is not sequencing speed, but interpretation, counselling, follow-up, and the full care pathway that turns data into something useful.</p><p>Sandy pushes on the fairness question too: if genomic foresight becomes a public good, who gets access, who pays, and what happens if it becomes another divide between wealthy families and everyone else?</p><p>If you care about genetics, public health, medical ethics, or the future of personalised medicine, this conversation is essential listening. It is a sharp, accessible look at how close we are to sequencing every baby, and why the real debate is not whether we can do it, but whether we should.</p>no00:35:0428The New Body Economy Part 5: The Newborn Genomefull<![CDATA[The New Body Economy Part 4: Women’s Health Is Not a Niche]]>Women’s health is not a niche market, it’s a massive blind spot in medicine, investment, and product design.

Ross Cagan and Sandy Weir unpack how decades of male-default research created real-world harm, from delayed diagnoses to missed heart attacks, and why that neglect is now becoming one of the biggest opportunities in health. They break down the data problem at the centre of the women’s health gap, including why female biology was historically excluded from studies, why that assumption turned out to be wrong, and how missing data leads to missing diagnoses. You’ll hear why endometriosis can take 8 to 10 years to diagnose, how menopause affects careers and productivity, and why cardiovascular disease is still misread in women more often than it should be.

Ross and Sandy also explore the rise of FemTech, from period tracking and fertility apps to pelvic health, contraception, and non-invasive diagnostics, and why the category needed a name before investors would take it seriously. They dig into the privacy and governance risks around sensitive reproductive data, especially after Roe v. Wade was overturned, and ask what happens when wellness tools sit somewhere between consumer app and medical advice.

You’ll also discover:

  • Why a meta-analysis of 293 studies challenged the old excuse for excluding female mice from research
  • How non-invasive testing could shorten the road to endometriosis diagnosis
  • Why menopause is both a health issue and a workforce issue
  • What the women’s health market could mean economically if the gap is finally closed

This conversation makes one thing clear: women’s health is a stress test for whether medicine can correct its own blind spots. It’s essential listening if you care about better care, better data, and a health system that serves half the population as more than an afterthought.

]]>01670569-1811-46f0-91dd-100b1292ed3fTue, 29 Sep 2026 19:04:10 GMT<p>Women’s health is not a niche market, it’s a massive blind spot in medicine, investment, and product design.</p><p>Ross Cagan and Sandy Weir unpack how decades of male-default research created real-world harm, from delayed diagnoses to missed heart attacks, and why that neglect is now becoming one of the biggest opportunities in health. They break down the data problem at the centre of the women’s health gap, including why female biology was historically excluded from studies, why that assumption turned out to be wrong, and how missing data leads to missing diagnoses. You’ll hear why endometriosis can take 8 to 10 years to diagnose, how menopause affects careers and productivity, and why cardiovascular disease is still misread in women more often than it should be.</p><p>Ross and Sandy also explore the rise of FemTech, from period tracking and fertility apps to pelvic health, contraception, and non-invasive diagnostics, and why the category needed a name before investors would take it seriously. They dig into the privacy and governance risks around sensitive reproductive data, especially after Roe v. Wade was overturned, and ask what happens when wellness tools sit somewhere between consumer app and medical advice.</p><p>You’ll also discover:</p><ul><li>Why a meta-analysis of 293 studies challenged the old excuse for excluding female mice from research</li><li>How non-invasive testing could shorten the road to endometriosis diagnosis</li><li>Why menopause is both a health issue and a workforce issue</li><li>What the women’s health market could mean economically if the gap is finally closed</li></ul><p>This conversation makes one thing clear: women’s health is a stress test for whether medicine can correct its own blind spots. It’s essential listening if you care about better care, better data, and a health system that serves half the population as more than an afterthought.</p>no00:27:59127The New Body Economy Part 4: Women’s Health Is Not a Nichefull<![CDATA[The New Body Economy Part 3: The Private Scan Boom]]>Private full-body MRIs are booming - but are you buying peace of mind or simply new things to worry about? Healthy people are lining up for scans that promise certainty, early detection, and control. Sandy Weir and Ross Cagan reveal why that promise can backfire, turning reassurance into anxiety, follow-up tests, and overdiagnosis. This episode unpacks the private scan boom and the uncomfortable truth behind elective whole-body MRI. Ross and Sandy explain why scanning a healthy body is not the same as investigating symptoms, and why the difference matters more than most marketing ever admits. When a scan finds a tiny cyst, nodule, or shadow, the question is not just "what is it?", it is "can you unsee it?"

]]>616a34e7-89a0-466c-a25f-5c95e5ce393dMon, 21 Sep 2026 22:40:53 GMT<p><b>Private full-body MRIs are booming - but are you buying peace of mind or simply new things to worry about? </b>Healthy people are lining up for scans that promise certainty, early detection, and control. Sandy Weir and Ross Cagan reveal why that promise can backfire, turning reassurance into anxiety, follow-up tests, and overdiagnosis. This episode unpacks the private scan boom and the uncomfortable truth behind elective whole-body MRI. Ross and Sandy explain why scanning a healthy body is not the same as investigating symptoms, and why the difference matters more than most marketing ever admits. When a scan finds a tiny cyst, nodule, or shadow, the question is not just "what is it?", it is "can you unsee it?"</p>no00:37:38126The New Body Economy Part 3: The Private Scan Boomfull<![CDATA[The New Body Economy Part 2: Forever Young?]]>Most longevity clinics are selling a seductive story, not proven results. If you care about biological age tests, rapamycin, supplements, or the booming market for “optimization,” this episode separates the real science from the expensive theatre. Ross Cagan and Sandy Weir take on the new body economy and ask the question at the centre of the longevity clinic boom: what actually improves health span, and what is just measurement, hope, and status wrapped in a premium price tag? The answer is more nuanced than the hype suggests, and far less magical than the marketing.

]]>54340f5c-73f7-44d3-a431-7e1c56dd7d9fThu, 10 Sep 2026 07:30:00 GMT<p>Most longevity clinics are selling a seductive story, not proven results. If you care about biological age tests, rapamycin, supplements, or the booming market for “optimization,” this episode separates the real science from the expensive theatre. Ross Cagan and Sandy Weir take on the new body economy and ask the question at the centre of the longevity clinic boom: what actually improves health span, and what is just measurement, hope, and status wrapped in a premium price tag? The answer is more nuanced than the hype suggests, and far less magical than the marketing.</p>no00:31:06125The New Body Economy Part 2: Forever Young?full<![CDATA[The New Body Economy Part 1: The Ozempic Economy]]>The Ozempic economy is already reshaping what people eat, how companies sell, and which health systems can afford to keep up. Sandy Weir and Ross Kagan kick off The Body Economy, a six-part series that starts with the drugs behind the headlines and ends with a much bigger question: what happens when appetite itself becomes medically adjustable?

]]>bc3fe5be-273d-406e-9d0a-b289a79467f9Fri, 04 Sep 2026 14:03:28 GMT<p>The Ozempic economy is already reshaping what people eat, how companies sell, and which health systems can afford to keep up. Sandy Weir and Ross Kagan kick off The Body Economy, a six-part series that starts with the drugs behind the headlines and ends with a much bigger question: what happens when appetite itself becomes medically adjustable?</p>no00:32:53124The New Body Economy Part 1: The Ozempic Economyfull<![CDATA[Billion-Dollar Blunder? Fleming and the Discovery of Antibiotics]]>One contaminated lab plate helped launch a multi-billion-dollar industry, save hundreds of millions of lives, and trigger one of the biggest IP blunders in British history. Ross Cagan and Sandy Weir trace the penicillin story from Alexander Fleming's messy "failed" experiment to the commercialisation race that changed medicine forever. They unpack how Fleming spotted the blue-green mould that killed staph bacteria, why his breakthrough sat ignored for a decade, and how Howard Florey and Ernest Chain turned the discovery into a scalable manufacturing process during World War Two. Along the way, they reveal why the real breakthrough wasn't just scientific, it was industrial, legal, and deeply political.

]]>1a106197-bff3-40a1-b9b4-bcc2efd7a924Thu, 27 Aug 2026 21:58:20 GMT<p>One contaminated lab plate helped launch a multi-billion-dollar industry, save hundreds of millions of lives, and trigger one of the biggest IP blunders in British history. Ross Cagan and Sandy Weir trace the penicillin story from Alexander Fleming's messy "failed" experiment to the commercialisation race that changed medicine forever. They unpack how Fleming spotted the blue-green mould that killed staph bacteria, why his breakthrough sat ignored for a decade, and how Howard Florey and Ernest Chain turned the discovery into a scalable manufacturing process during World War Two. Along the way, they reveal why the real breakthrough wasn't just scientific, it was industrial, legal, and deeply political.</p>no00:19:38123Billion-Dollar Blunder? Fleming and the Discovery of Antibioticsfull<![CDATA[E22: Bio-Economics of Murder: The Jigsaw Murders]]>A doctor tried to erase two murders so completely that he turned the crime scene into a puzzle.

What finally exposed the truth was not a confession, but forensic ingenuity; skull reconstruction, photographic superimposition, and insects that could timestamp death with uncanny precision.

Ross Cagan and Sandy Weir unpack the infamous Buck Ruxton case, known as the Jigsaw Murders and Bodies Under the Bridge, and show how a 1935 killing in Moffat helped redefine modern forensic science.

]]>1c717d5c-6348-41d4-8553-645c22ab8564Thu, 20 Aug 2026 22:32:38 GMT<p>A doctor tried to erase two murders so completely that he turned the crime scene into a puzzle.</p><p></p><p>What finally exposed the truth was not a confession, but forensic ingenuity; skull reconstruction, photographic superimposition, and insects that could timestamp death with uncanny precision.</p><p></p><p>Ross Cagan and Sandy Weir unpack the infamous Buck Ruxton case, known as the Jigsaw Murders and Bodies Under the Bridge, and show how a 1935 killing in Moffat helped redefine modern forensic science.</p>no00:26:04122E22: Bio-Economics of Murder: The Jigsaw Murdersfull<![CDATA[E21: What Actually is the Placebo Effect? Part II]]>The placebo effect is far more powerful, and potentially more dangerous, than most people realise. Expectation can trigger real biochemical changes in the brain, ease symptoms, and even nudge dopamine release in Parkinson's disease, but it can also create side effects out of thin air and quietly distort treatment decisions.

In the second part of their examination of the placebo effect, Sandy Weir and Ross Cagan dig further into the science behind placebo and nocebo, showing why "feeling better" is not the same as "being better." They use striking examples from Parkinson's, asthma, COVID vaccine trials, pain relief, and cancer care to show where placebo responses help, where they mislead, and why the line matters so much in real medicine.

]]>52096c72-a899-4bfc-b690-6b26ef7ea0a2Thu, 13 Aug 2026 21:46:10 GMT<p>The placebo effect is far more powerful, and potentially more dangerous, than most people realise. Expectation can trigger real biochemical changes in the brain, ease symptoms, and even nudge dopamine release in Parkinson's disease, but it can also create side effects out of thin air and quietly distort treatment decisions.<br /><br />In the second part of their examination of the placebo effect, Sandy Weir and Ross Cagan dig further into the science behind placebo and nocebo, showing why "feeling better" is not the same as "being better." They use striking examples from Parkinson's, asthma, COVID vaccine trials, pain relief, and cancer care to show where placebo responses help, where they mislead, and why the line matters so much in real medicine.</p>no00:40:56121E21: What Actually is the Placebo Effect? Part IIfull<![CDATA[E20: What Actually IS The Placebo Effect? Part I]]>A fake surgery that performed as well as the real thing. That’s the kind of result that changes how you think about pain, healing, and what medicine actually is.

In this episode Ross and Sandy break down why the placebo effect is not “mind over matter” trivia, but real biology shaped by expectation, trust, ritual, and meaning.

They use one of the most famous knee surgery studies to expose the gap between what’s happening in the operating theatre and what the body is actually responding to. If you’ve ever wondered why some treatments work better in practice than they should on paper, this conversation shows you where the hidden power lives.

Ross explains the science of precision medicine and the role of meaning in the health system, while Sandy brings the lens of technology, investment, and health innovation. Together they show why medicine is not just chemistry, but chemistry delivered through theatre, and why that distinction matters when patients, doctors, and investors are trying to understand what really works.

]]>016f41a0-806c-4f28-aba6-6392db377988Fri, 07 Aug 2026 07:59:28 GMT<p>A fake surgery that performed as well as the real thing. That’s the kind of result that changes how you think about pain, healing, and what medicine actually is.</p><p></p><p>In this episode Ross and Sandy break down why the placebo effect is not “mind over matter” trivia, but real biology shaped by expectation, trust, ritual, and meaning.</p><p></p><p>They use one of the most famous knee surgery studies to expose the gap between what’s happening in the operating theatre and what the body is actually responding to. If you’ve ever wondered why some treatments work better in practice than they should on paper, this conversation shows you where the hidden power lives.</p><p></p><p>Ross explains the science of precision medicine and the role of meaning in the health system, while Sandy brings the lens of technology, investment, and health innovation. Together they show why medicine is not just chemistry, but chemistry delivered through theatre, and why that distinction matters when patients, doctors, and investors are trying to understand what really works.</p>no00:35:53120E20: What Actually IS The Placebo Effect? Part Ifull<![CDATA[E19: The Bio-Founder's Playbook, Part 2b: How to Raise Funding in Scotland]]>Unlock the secrets to launching a biotech startup from Scotland’s leading experts; avoid common pitfalls, tap into critical funding sources, and learn when and how to scale beyond borders.

Most founders rush into company formation without the right foundation. Prof Ross Cagan, Director of the McNabb Center, and Dr Sandy Weir, Tech Innovation Leader, expose the biggest mistakes biotech entrepreneurs make when transitioning from research to business.

They reveal how to use university resources to de-risk your project, the true role of non-dilutive funding, and the importance of timing in fundraising. Discover why early company formation can hamper your growth and learn the smart steps to validate your idea, protect your IP, and build a credible team before pitching to investors.

In this episode, Ross and Sandy continue to share real-world insights from their vast experience, highlighting the difference between innovative science and investable companies.

They caution against rushing early, over-diluting, or pitching without thorough market and regulatory understanding. Plus, they offer practical tips for securing any startup milestone, backing Scotland’s vibrant biotech ecosystem, and building a truly global company.

Perfect for early-stage founders, biotech entrepreneurs, and researchers eager to turn their innovative ideas into impactful businesses. If you're ready to navigate the complex funding landscape and avoid costly pitfalls, this episode is your ultimate guide to raising capital, scaling smartly, and making a real difference in healthcare.

]]>f3040566-9152-47f7-98c4-93f0abbcbdecFri, 31 Jul 2026 16:35:23 GMT<p>Unlock the secrets to launching a biotech startup from Scotland’s leading experts; avoid common pitfalls, tap into critical funding sources, and learn when and how to scale beyond borders.</p><p></p><p>Most founders rush into company formation without the right foundation. Prof Ross Cagan, Director of the McNabb Center, and Dr Sandy Weir, Tech Innovation Leader, expose the biggest mistakes biotech entrepreneurs make when transitioning from research to business.</p><p></p><p>They reveal how to use university resources to de-risk your project, the true role of non-dilutive funding, and the importance of timing in fundraising. Discover why early company formation can hamper your growth and learn the smart steps to validate your idea, protect your IP, and build a credible team before pitching to investors.</p><p>In this episode, Ross and Sandy continue to share real-world insights from their vast experience, highlighting the difference between innovative science and investable companies.</p><p></p><p>They caution against rushing early, over-diluting, or pitching without thorough market and regulatory understanding. Plus, they offer practical tips for securing any startup milestone, backing Scotland’s vibrant biotech ecosystem, and building a truly global company.</p><p></p><p>Perfect for early-stage founders, biotech entrepreneurs, and researchers eager to turn their innovative ideas into impactful businesses. If you're ready to navigate the complex funding landscape and avoid costly pitfalls, this episode is your ultimate guide to raising capital, scaling smartly, and making a real difference in healthcare.</p>no00:35:18119E19: The Bio-Founder's Playbook, Part 2b: How to Raise Funding in Scotlandfull<![CDATA[E18: The Bio-Founder’s Playbook, Part 2 (a): How to Raise Funding in Scotland]]>Unlock the secrets to turning innovative Scotland-based life sciences ideas into global success stories.

This episode dives into the practical steps, funding strategies, legal hurdles, and insider tips, needed to transform early research into a thriving company, all while avoiding costly mistakes. Whether you're a scientist at the start of your entrepreneurial journey or an investor looking to spot a winning biotech, this episode will elevate your understanding of the complex landscape of life science startups.

Ross, a Professor of Precision Medicine, and Sandy, a Tech Innovation Leader, lay out the critical map for founders: When to stay in academia and when to get out, how university support can be a fortress or a trap, and why dilution and IP are your biggest enemies early on. Discover why forming a company too soon can stall your progress, how early grants can jumpstart your journey, and the subtle art of pitching investors with a sharp focus on milestones, market opportunity, and control—not just science coolness.

]]>0168955d-a500-4e30-b6e3-0d11acb3327eThu, 23 Jul 2026 07:30:00 GMT<p>Unlock the secrets to turning innovative Scotland-based life sciences ideas into global success stories.</p><p></p><p>This episode dives into the practical steps, funding strategies, legal hurdles, and insider tips, needed to transform early research into a thriving company, all while avoiding costly mistakes. Whether you're a scientist at the start of your entrepreneurial journey or an investor looking to spot a winning biotech, this episode will elevate your understanding of the complex landscape of life science startups.</p><p></p><p>Ross, a Professor of Precision Medicine, and Sandy, a Tech Innovation Leader, lay out the critical map for founders: When to stay in academia and when to get out, how university support can be a fortress or a trap, and why dilution and IP are your biggest enemies early on. Discover why forming a company too soon can stall your progress, how early grants can jumpstart your journey, and the subtle art of pitching investors with a sharp focus on milestones, market opportunity, and control—not just science coolness.</p>no00:41:57118E18: The Bio-Founder’s Playbook, Part 2 (a): How to Raise Funding in Scotlandfull<![CDATA[E17: The Bio-Founder’s Playbook (Part 1): Explaining Funding Jargon]]>Most biotech founders in Scotland and beyond don’t understand the complex world of venture capital. This episode reveals the insider secrets to navigating early-stage biotech funding, from bootstrap beginnings to Series C success, with insights you won’t find anywhere else.

Whether you're a scientist dreaming of transforming your research into a life-changing medicine or an investor eager to unlock the next big breakthrough, this is your ultimate crash course in biotech funding.

Ross Cagan and Sandy Weir team-up to demystify the funding pipeline that every life sciences entrepreneur must master.

You’ll discover why biotech is so fundamentally different from software startups, and why understanding this difference is crucial if you want your innovation to reach patients, not just papers. They unpack the entire funding journey: from bootstrapping with friends and family, to angel investments, the seed rounds that prove market need, and on to Series A, B, and beyond, culminating in a strategic exit or IPO.

Get ready to learn how these stages work in Scotland, the UK, and even compare them to the US landscape, with practical insights on costs, timelines, and what investors are really after.

]]>5dda39b8-59a8-4f8a-aa38-cba4b20f6fd9Fri, 17 Jul 2026 10:06:18 GMT<p>Most biotech founders in Scotland and beyond don’t understand the complex world of venture capital. This episode reveals the insider secrets to navigating early-stage biotech funding, from bootstrap beginnings to Series C success, with insights you won’t find anywhere else.</p><p></p><p>Whether you're a scientist dreaming of transforming your research into a life-changing medicine or an investor eager to unlock the next big breakthrough, this is your ultimate crash course in biotech funding.</p><p>Ross Cagan and Sandy Weir team-up to demystify the funding pipeline that every life sciences entrepreneur must master.</p><p></p><p>You’ll discover why biotech is so fundamentally different from software startups, and why understanding this difference is crucial if you want your innovation to reach patients, not just papers. They unpack the entire funding journey: from bootstrapping with friends and family, to angel investments, the seed rounds that prove market need, and on to Series A, B, and beyond, culminating in a strategic exit or IPO.</p><p>Get ready to learn how these stages work in Scotland, the UK, and even compare them to the US landscape, with practical insights on costs, timelines, and what investors are really after.</p>no00:56:43117E17: The Bio-Founder’s Playbook (Part 1): Explaining Funding Jargonfull<![CDATA[E16: The Memory Economy: Dementia and Fighting for Our Future]]>In this episode Ross and Sandy discuss the complexities of dementia, exploring its impact, the science behind it, the economic costs, and the biotech industry's efforts in prevention and early detection. The conversation covers the future of disease treatment, encouraging industry to explore opportunities, practical and personal advice for disease prevention. We close with our 'wee bit of joy' and consider Scotland's struggle in the Football World Cup, a family reunion in New York, and establishing a transatlantic traditions.

]]>fea8df77-231e-47d5-b0fe-506e534da252Wed, 08 Jul 2026 07:30:00 GMT<p>In this episode Ross and Sandy discuss the complexities of dementia, exploring its impact, the science behind it, the economic costs, and the biotech industry's efforts in prevention and early detection. The conversation covers the future of disease treatment, encouraging industry to explore opportunities, practical and personal advice for disease prevention. We close with our 'wee bit of joy' and consider Scotland's struggle in the Football World Cup, a family reunion in New York, and establishing a transatlantic traditions.</p>no00:40:55116E16: The Memory Economy: Dementia and Fighting for Our Futurefull<![CDATA[E15: Scotland's Cardiovascular Crisis]]>Most companies overlook a massive opportunity in early diagnosis for cardiovascular disease, and the stakes couldn’t be higher.

On this episode of The Long Game, Ross and Sandy reveal how Scotland’s thriving biotech ecosystem is turning understanding of the “broken heart” into ground breaking tech that could save lives and billions in healthcare costs.

Right now, Scotland faces an alarming crisis: a stunning one-third of all deaths are caused by heart disease, stroke, and related vascular conditions, and it hits women twice as hard as breast cancer. Despite common myths, heart disease is not just an "old man's disease"—it’s the leading killer of women too, and it often goes unnoticed until it's too late. You’ll discover compelling data that shatters misconceptions, showing how genetics, lifestyle, and stark health inequalities combine to make cardiovascular disease Scotland’s #1 health burden.

We break down how early diagnostics, innovative imaging techniques, and leveraging Scotland’s rich health data can tip the balance. You'll learn about the Scottish initiatives that use AI and predictive analytics to catch heart issues before they become catastrophic. Plus, Sandy shares how the Scottish biotech scene is poised to turn these insights into impactful startups, and the crucial role entrepreneurs can play in driving structural cost savings for the NHS.

Missing this opportunity means accepting inevitability and delaying action that could save lives and billions. Meanwhile, detailed research and tech innovation promise a future where early detection is standard, and preventable deaths drop significantly. This isn’t just science; it’s an economic game-changer for Scotland and beyond.

]]>5ef4f4ea-c6ba-4cdb-ba49-2cab7252593aTue, 30 Jun 2026 07:30:00 GMT<p>Most companies overlook a massive opportunity in early diagnosis for cardiovascular disease, and the stakes couldn’t be higher.</p><p></p><p>On this episode of <i>The Long Game</i>, Ross and Sandy reveal how Scotland’s thriving biotech ecosystem is turning understanding of the “broken heart” into ground breaking tech that could save lives and billions in healthcare costs.</p><p></p><p>Right now, Scotland faces an alarming crisis: a stunning one-third of all deaths are caused by heart disease, stroke, and related vascular conditions, and it hits women twice as hard as breast cancer. Despite common myths, heart disease is not just an "old man's disease"—it’s the leading killer of women too, and it often goes unnoticed until it's too late. You’ll discover compelling data that shatters misconceptions, showing how genetics, lifestyle, and stark health inequalities combine to make cardiovascular disease Scotland’s #1 health burden.</p><p></p><p>We break down how early diagnostics, innovative imaging techniques, and leveraging Scotland’s rich health data can tip the balance. You'll learn about the Scottish initiatives that use AI and predictive analytics to catch heart issues before they become catastrophic. Plus, Sandy shares how the Scottish biotech scene is poised to turn these insights into impactful startups, and the crucial role entrepreneurs can play in driving structural cost savings for the NHS.</p><p></p><p>Missing this opportunity means accepting inevitability and delaying action that could save lives and billions. Meanwhile, detailed research and tech innovation promise a future where early detection is standard, and preventable deaths drop significantly. This isn’t just science; it’s an economic game-changer for Scotland and beyond.</p>no00:35:41115E15: Scotland's Cardiovascular Crisisfull<![CDATA[E14: Bio-Economics of Murder - The Glasgow Poisoner]]>Most medical trust is based on a simple signature, until it isn’t. A 19th-century Glasgow doctor’s deadly misuse of that trust not only shocked the nation but also helped shape the foundation of modern forensic science. Discover how one man’s dark deeds as the "Glasgow Poisoner" exposed horrifying weaknesses in a system that still challenges us today and why verifying trust has never been more crucial.

In this gripping episode, Sandy and Ross unravel the true story of Dr. Edward William Pritchard, a respected doctor turned murderer, who used his medical knowledge to commit the perfect crime. You’ll learn how his use of poisons like aconite and antimony mimicked natural illnesses, hiding his devilish handiwork for weeks.

We break down the evolution of forensic toxicology, highlighting the ground breaking forensic methods born from this case; methods that still protect us. You'll discover how this early scientific triumph paved the way for today's standards, and why trusted authorities must always be scrutinised.

]]>cae61bb3-082d-406b-8537-2c4205050c65Wed, 24 Jun 2026 07:30:00 GMT<p>Most medical trust is based on a simple signature, until it isn’t. A 19th-century Glasgow doctor’s deadly misuse of that trust not only shocked the nation but also helped shape the foundation of modern forensic science. Discover how one man’s dark deeds as the "Glasgow Poisoner" exposed horrifying weaknesses in a system that still challenges us today and why verifying trust has never been more crucial.</p><p></p><p>In this gripping episode, Sandy and Ross unravel the true story of Dr. Edward William Pritchard, a respected doctor turned murderer, who used his medical knowledge to commit the perfect crime. You’ll learn how his use of poisons like aconite and antimony mimicked natural illnesses, hiding his devilish handiwork for weeks.</p><p></p><p>We break down the evolution of forensic toxicology, highlighting the ground breaking forensic methods born from this case; methods that still protect us. You'll discover how this early scientific triumph paved the way for today's standards, and why trusted authorities must always be scrutinised.</p>no00:28:36114E14: Bio-Economics of Murder - The Glasgow Poisonerfull<![CDATA[E13: AI to Cure (Part 3) - Hacking Our Brains]]>In this episode we attempt to uncover how AI is transforming the human mind, from decoding thoughts to rewriting emotions. Imagine a future where your dreams, memories, and even your emotional states are not private. We delve into the mind-bending capabilities of cutting-edge AI that’s learning to read, modify, and potentially control our inner worlds. From neural implants that detect and influence anxiety to machine-designed neurons that communicate directly with our brains, the boundary between science fiction and reality is vanishing fast.

]]>5816b5f7-1a0a-42e5-8211-4a3e3b0f7cb9Wed, 17 Jun 2026 07:30:00 GMT<p>In this episode we attempt to uncover how AI is transforming the human mind, from decoding thoughts to rewriting emotions. Imagine a future where your dreams, memories, and even your emotional states are not private. We delve into the mind-bending capabilities of cutting-edge AI that’s learning to read, modify, and potentially control our inner worlds. From neural implants that detect and influence anxiety to machine-designed neurons that communicate directly with our brains, the boundary between science fiction and reality is vanishing fast.</p>no00:33:43113E13: AI to Cure (Part 3) - Hacking Our Brainsfull<![CDATA[E12: AI to Cure (Part 2) – Drugs and Digital Twins]]>In this episode Ross and Sandy delve into the applications of AI in biology, drug discovery, and clinical trials, highlighting the potential of AI to revolutionize the healthcare industry. It explores the role of AI in drug design, protein modelling, gene editing, and cancer vaccines, as well as the challenges and opportunities in clinical trials and drug approval. The conversation delves into the concept of digital twins and their application in healthcare, particularly in simulating human organs and clinical trial design. It also explores the transformative potential of digital twins for rare diseases and the ethical implications of using AI in healthcare. The discussion concludes with a reflection on the impact of AI on biology and the need for responsible decision-making.

]]>210b0ecf-0518-4f63-a6a8-417b7be0e724Tue, 09 Jun 2026 07:30:00 GMT<p>In this episode Ross and Sandy delve into the applications of AI in biology, drug discovery, and clinical trials, highlighting the potential of AI to revolutionize the healthcare industry. It explores the role of AI in drug design, protein modelling, gene editing, and cancer vaccines, as well as the challenges and opportunities in clinical trials and drug approval. The conversation delves into the concept of digital twins and their application in healthcare, particularly in simulating human organs and clinical trial design. It also explores the transformative potential of digital twins for rare diseases and the ethical implications of using AI in healthcare. The discussion concludes with a reflection on the impact of AI on biology and the need for responsible decision-making.</p>no00:50:53112E12: AI to Cure (Part 2) – Drugs and Digital Twinsfull<![CDATA[E10.2: Novabiotics and the NE Ecosystem - The Deborah O'Neil Interview]]>In part 2 of this episode, Ross and Sandy continue their conversation with Dr. Deborah O'Neill where we discusses her leadership in the biotech industry, the challenges in biotech infrastructure, the economic impact of life sciences, regional investment and opportunities, and creative problem solving in the industry.

]]>955815d5-b406-4148-b88e-c6e617489653Sun, 31 May 2026 11:12:18 GMT<p>In part 2 of this episode, Ross and Sandy continue their conversation with Dr. Deborah O'Neill where we discusses her leadership in the biotech industry, the challenges in biotech infrastructure, the economic impact of life sciences, regional investment and opportunities, and creative problem solving in the industry.</p>no00:28:34111E10.2: Novabiotics and the NE Ecosystem - The Deborah O'Neil Interviewfull<![CDATA[E10.1: NovaBiotics and the NE Ecosystem - The Deborah O'Neil Interview]]>In this episode, join Ross and Sandy in discussion with Dr. Deborah O'Neill, CEO of NovaBiotics. Released in two parts, in this first part of the interview Deborah discusses her journey from academia to entrepreneurship, sharing insights into the science and story behind the formation of NovaBiotics. We hear about the fascinating work they are doing to combat microbial resistance and the potential impact of their developments for cystic fibrosis patients. Throughout this episode she highlights the importance of place, Aberdeen in the North East of Scotland, but we will dig deeper into this part of the story in part 2. For now we focus on the science and the biology. Enjoy!

]]>4cf4f725-679e-405e-bf0c-3ecfa30b4fbaFri, 29 May 2026 07:30:00 GMT<p>In this episode, join Ross and Sandy in discussion with Dr. Deborah O'Neill, CEO of NovaBiotics. Released in two parts, in this first part of the interview Deborah discusses her journey from academia to entrepreneurship, sharing insights into the science and story behind the formation of NovaBiotics. We hear about the fascinating work they are doing to combat microbial resistance and the potential impact of their developments for cystic fibrosis patients. Throughout this episode she highlights the importance of place, Aberdeen in the North East of Scotland, but we will dig deeper into this part of the story in part 2. For now we focus on the science and the biology. Enjoy!</p>no00:27:24110E10.1: NovaBiotics and the NE Ecosystem - The Deborah O'Neil Interviewfull<![CDATA[E9: AI to Cure: Saving Lives or Sacking Staff?]]>In this episode, the principal themes revolve around the application of AI in healthcare, focusing on efficiency, productivity, and patient care. The discussion also delves into the concept of virtual hospitals, the impact of AI on radiology imaging, and its role in emergency services.

]]>14070075-7cef-4871-8700-3c7c559d7326Wed, 20 May 2026 07:30:00 GMT<p>In this episode, the principal themes revolve around the application of AI in healthcare, focusing on efficiency, productivity, and patient care. The discussion also delves into the concept of virtual hospitals, the impact of AI on radiology imaging, and its role in emergency services.</p>no00:28:2819E9: AI to Cure: Saving Lives or Sacking Staff?full<![CDATA[E8: Aberdeen's Half-mad Scientists and the birth of MRI]]>In this episode Ross and Sandy explore the history and impact of MRI technology, highlighting its development in Scotland and its global significance. It delves into the challenges and breakthroughs in medical imaging, emphasising the contributions of Scottish scientists and the commercial impact of their innovations.

]]>00542421-1c1f-49c3-b501-dd9404fd50fcWed, 13 May 2026 07:00:00 GMT<p>In this episode Ross and Sandy explore the history and impact of MRI technology, highlighting its development in Scotland and its global significance. It delves into the challenges and breakthroughs in medical imaging, emphasising the contributions of Scottish scientists and the commercial impact of their innovations.</p>no00:29:2418E8: Aberdeen's Half-mad Scientists and the birth of MRIfull<![CDATA[E7: The Infrastructure Crisis - Where to Put Your Biotech?]]>Most biotech start-ups struggle just to find space, but Scotland is pioneering a solution that could revolutionise how life sciences companies grow and thrive.

In this episode Ross and Sandy peel back the curtain on the critical infrastructure bottleneck threatening Scotland’s $25 billion biotech ambitions, revealing how innovative models and hefty public investment are building state-of-the-art shared lab hubs to retain top talent and accelerate breakthroughs.

You’ll discover what makes wet labs so fundamentally different from office space, from the complex HVAC and plumbing requirements to vibration-sensitive machinery that demands specialized, expensive infrastructure. Ross and Sandy break down the staggering costs that push startups out of the UK’s golden triad of London, Oxford, and Cambridge, while exploring the ambitious Scottish initiatives to close that gap with a £55 million public-private drive. They share how Scotland’s new incubator programs and the recently opened Health Innovation Hub are creating shared, high-spec facilities designed specifically to meet the demands of biotech and healthcare innovation.

They dive into why location matters more than ever; proximity to hospitals, universities, and a vibrant network of scientists fuels deeper collaboration, faster research, and a more resilient ecosystem. With insights from experts involved in these projects, this episode reveals how Scotland’s strategic focus on infrastructure could turn the tide against brain drain, transforming the country into a biotech powerhouse. Whether you’re a founder, investor, or policy-maker, understanding this infrastructure battle is essential for shaping the future of life sciences.

Perfect for entrepreneurs dreaming of building breakthroughs, investors looking to capitalize on a booming sector, or anyone passionate about regional innovation, this episode unlocks some of the secrets to making biotech ecosystems thrive from the ground up. Tune in to hear how Scotland’s bold approach is rewriting the rules of biotech growth, one shared lab at a time.

]]>45b6cebb-a102-4a1d-8fe0-56f6da959847Wed, 06 May 2026 15:14:58 GMT<p>Most biotech start-ups struggle just to find space, but Scotland is pioneering a solution that could revolutionise how life sciences companies grow and thrive.</p><p></p><p>In this episode Ross and Sandy peel back the curtain on the critical infrastructure bottleneck threatening Scotland’s $25 billion biotech ambitions, revealing how innovative models and hefty public investment are building state-of-the-art shared lab hubs to retain top talent and accelerate breakthroughs.</p><p></p><p>You’ll discover what makes wet labs so fundamentally different from office space, from the complex HVAC and plumbing requirements to vibration-sensitive machinery that demands specialized, expensive infrastructure. Ross and Sandy break down the staggering costs that push startups out of the UK’s golden triad of London, Oxford, and Cambridge, while exploring the ambitious Scottish initiatives to close that gap with a £55 million public-private drive. They share how Scotland’s new incubator programs and the recently opened Health Innovation Hub are creating shared, high-spec facilities designed specifically to meet the demands of biotech and healthcare innovation.</p><p></p><p>They dive into why location matters more than ever; proximity to hospitals, universities, and a vibrant network of scientists fuels deeper collaboration, faster research, and a more resilient ecosystem. With insights from experts involved in these projects, this episode reveals how Scotland’s strategic focus on infrastructure could turn the tide against brain drain, transforming the country into a biotech powerhouse. Whether you’re a founder, investor, or policy-maker, understanding this infrastructure battle is essential for shaping the future of life sciences.</p><p></p><p>Perfect for entrepreneurs dreaming of building breakthroughs, investors looking to capitalize on a booming sector, or anyone passionate about regional innovation, this episode unlocks some of the secrets to making biotech ecosystems thrive from the ground up. Tune in to hear how Scotland’s bold approach is rewriting the rules of biotech growth, one shared lab at a time.</p>no00:30:3917E7: The Infrastructure Crisis - Where to Put Your Biotech?full<![CDATA[E6: Is Scotland’s Patient Data the New Oil?]]>In this episode we explore the economics of the health data revolution and learn about how a surprising and relatively unknown archive in Scotland could change everything. What if your genetic history, kept since 1965 in a vault, is the ultimate resource for life sciences innovation? This episode reveals how Scotland’s hidden DNA archive (over 2.5 million newborn blood cards) may be the key to revolutionising personalised medicine and global healthcare, all while safeguarding public trust.

]]>d659f15f-1552-4c36-9c9c-31b93bf16619Tue, 28 Apr 2026 08:42:02 GMT<p>In this episode we explore the economics of the health data revolution and learn about how a surprising and relatively unknown archive in Scotland could change everything. What if your genetic history, kept since 1965 in a vault, is the ultimate resource for life sciences innovation? This episode reveals how Scotland’s hidden DNA archive (over 2.5 million newborn blood cards) may be the key to revolutionising personalised medicine and global healthcare, all while safeguarding public trust.</p>no00:32:4816E6: Is Scotland’s Patient Data the New Oil?full<![CDATA[E5 - Cancer 101 and the Business of Curing It]]>In this conversation Ross and Sandy delve into the complexity of cancer, the challenges in finding a cure, and the innovative approaches being pursued in the field of oncology. It also explores the economic impact of cancer research and the potential for the Scottish biotech ecosystem. The discussion emphasizes the need to embrace the chaos of cancer and the business opportunities it presents.

]]>ee74ae1a-3f71-4e97-a0a6-d6d414eb4468Tue, 21 Apr 2026 08:30:37 GMT<p>In this conversation Ross and Sandy delve into the complexity of cancer, the challenges in finding a cure, and the innovative approaches being pursued in the field of oncology. It also explores the economic impact of cancer research and the potential for the Scottish biotech ecosystem. The discussion emphasizes the need to embrace the chaos of cancer and the business opportunities it presents.</p>no00:31:5715E5 - Cancer 101 and the Business of Curing Itfull<![CDATA[E4: The New Reality of Living Long with Cancer- Interviewing Andrew Biankin]]>Most people think of cancer research as solely focused on survival, but what happens when the goal shifts from "get past five years" to "live long with cancer"? In this episode, we explore the game-changing trend transforming oncology from a battle against death to a fight for quality of life.
Join Ross and Sandy as they sit down with world-renowned surgeon and cancer scientist, Professor Andrew Biankin, to uncover how decades of research have turned lethal cancers into manageable, chronic conditions. Discover why the focus must now go beyond new drugs toward better patient stratification, smarter resource allocation, and a more nuanced approach to long-term care.

]]>691d6ff8-3a55-4822-85fb-2dda883d803cTue, 14 Apr 2026 08:25:42 GMT<p>Most people think of cancer research as solely focused on survival, but what happens when the goal shifts from "get past five years" to "live long with cancer"? In this episode, we explore the game-changing trend transforming oncology from a battle against death to a fight for quality of life.<br />Join Ross and Sandy as they sit down with world-renowned surgeon and cancer scientist, Professor Andrew Biankin, to uncover how decades of research have turned lethal cancers into manageable, chronic conditions. Discover why the focus must now go beyond new drugs toward better patient stratification, smarter resource allocation, and a more nuanced approach to long-term care.</p>no00:39:1214E4: The New Reality of Living Long with Cancer- Interviewing Andrew Biankinfull<![CDATA[E3: The Oncocine Cancer Vaccine Story- Interview with Ishani Malhotra ]]>We are joined by Ishani Malhotra, Founder and CEO of Oncocine, for a conversation on personalised mRNA cancer vaccines, AI-driven precision medicine, and the realities of building a biotech company in Scotland. And, as always, we finish with our Wee Bit of Joy — this week featuring rugby, David Byrne and love, and a moment away from the lab bench.

]]>5be4d563-ef50-42cf-bcda-4768bc484771Thu, 09 Apr 2026 18:07:48 GMT<p>We are joined by Ishani Malhotra, Founder and CEO of Oncocine, for a conversation on personalised mRNA cancer vaccines, AI-driven precision medicine, and the realities of building a biotech company in Scotland. And, as always, we finish with our <i>Wee Bit of Joy</i> — this week featuring rugby, David Byrne and love, and a moment away from the lab bench.</p>no00:45:2913E3: The Oncocine Cancer Vaccine Story- Interview with Ishani Malhotra full<![CDATA[E2- The Biotech Scene in Scotland]]>In Episode 2 of The Long Game, Sandy Weir and Ross Cagan explore Scotland’s biotech ecosystem, from Glasgow and Edinburgh to Aberdeen, and discuss the science, capital, data, and ambition needed to build a £25 billion life sciences sector. They end with their traditional Wee Bit of Joy, from signs of spring and golf plans on Bute to an unexpected encounter with Scotland’s lapidary tradition.

]]>81fd49f7-49cc-4a73-a805-d8d682c5c709Thu, 02 Apr 2026 21:38:53 GMT<p>In <b>Episode 2 of <i>The Long Game</i></b>, Sandy Weir and Ross Cagan explore Scotland’s biotech ecosystem, from Glasgow and Edinburgh to Aberdeen, and discuss the science, capital, data, and ambition needed to build a £25 billion life sciences sector. They end with their traditional Wee Bit of Joy, from signs of spring and golf plans on Bute to an unexpected encounter with Scotland’s lapidary tradition.</p>no00:34:0012E2- The Biotech Scene in Scotlandfull<![CDATA[E0: Welcome to "The Long Game" Podcast]]>We are scientists, bioentrepreneurs, friends, and golf partners. In The Long Game, Sandy Weir and Ross Cagan use clear, friendly conversations to explore the science shaping our lives and driving Scotland’s biotech economy. In this introductory episode, we explain why we started the podcast, what questions we want to tackle, and how great ideas become real-world medicines, devices, and life sciences companies through science, translation, and innovation.

]]>019b6312-91f4-4fc5-a19c-d1dc67daf021Thu, 02 Apr 2026 21:23:22 GMT<p>We are scientists, bioentrepreneurs, friends, and golf partners. In <i>The Long Game</i>, Sandy Weir and Ross Cagan use clear, friendly conversations to explore the science shaping our lives and driving Scotland’s biotech economy. In this introductory episode, we explain why we started the podcast, what questions we want to tackle, and how great ideas become real-world medicines, devices, and life sciences companies through science, translation, and innovation.</p>no00:10:081E0: Welcome to "The Long Game" Podcastfull<![CDATA[E1: How We Die (& What It Costs)]]>In Episode 1 of The Long Game, Sandy Weir and Ross Cagan explore why people in Scotland die, what those patterns reveal about cancer, heart disease, dementia, and drug deaths, and why prevention and early diagnosis matter not only for health, but for the future of Scotland’s biotech economy.

]]>2f3ca48c-78a5-4b11-9e34-17ae5723e226Mon, 30 Mar 2026 20:33:54 GMT<p>In <b>Episode 1 of <i>The Long Game</i></b>, Sandy Weir and Ross Cagan explore why people in Scotland die, what those patterns reveal about cancer, heart disease, dementia, and drug deaths, and why prevention and early diagnosis matter not only for health, but for the future of Scotland’s biotech economy.</p>no00:25:4011E1: How We Die (& What It Costs)full